Massive study investigates sex differences in popular Heart-Kidney drugs

NCT ID NCT07188545

Ongoing Knowledge-focused Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at millions of medical records to see if GLP-1 agonists (like Ozempic) and SGLT2 inhibitors (like Jardiance) affect heart, kidney, and metabolic health differently in men versus women. Participants are adults with early-stage cardiovascular-kidney-metabolic syndrome who have taken these drugs. The goal is to find out if sex influences treatment outcomes, which could lead to more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 agonists (e.g., semaglutide) and SGLT2 inhibitors (e.g., empagliflozin)
What this could lead to: If it succeeds, this could show whether these drugs need to be tailored by sex for better heart, kidney, and metabolic health.
What could go wrong: This is an observational study using existing data, not a controlled trial, so it can't prove cause and effect. Results may be influenced by unmeasured factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder cardiovascular-kidney-metabolic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME

Contacts and locations

Locations

Ohio State University

Columbus, Ohio, 43202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.